Norpropoxyphene

Last updated
Norpropoxyphene
Norpropoxyphene Structure.svg
Names
Preferred IUPAC name
(2S,3R)-3-Methyl-4-(methylamino)-1,2-diphenylbutan-2-yl propanoate
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C21H27NO2/c1-4-20(23)24-21(17(2)16-22-3,19-13-9-6-10-14-19)15-18-11-7-5-8-12-18/h5-14,17,22H,4,15-16H2,1-3H3/t17-,21+/m1/s1 Yes check.svgY
    Key: IKACRWYHQXOSGM-UTKZUKDTSA-N Yes check.svgY
  • InChI=1/C21H27NO2/c1-4-20(23)24-21(17(2)16-22-3,19-13-9-6-10-14-19)15-18-11-7-5-8-12-18/h5-14,17,22H,4,15-16H2,1-3H3/t17-,21+/m1/s1
    Key: IKACRWYHQXOSGM-UTKZUKDTBF
  • O=C(O[C@@](c1ccccc1)(Cc2ccccc2)[C@H](C)CNC)CC
Properties
C21H27NO2
Molar mass 325.445
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Yes check.svgY  verify  (what is  Yes check.svgYX mark.svgN ?)

Norpropoxyphene is a major metabolite of the opioid analgesic drug dextropropoxyphene, [1] and is responsible for many of the side effects associated with use of this drug, especially the unusual toxicity seen during dextropropoxyphene overdose. [2] [3] [4] It has weaker analgesic effects than dextropropoxyphene itself, but is a relatively potent pro-convulsant and blocker of sodium and potassium channels, [5] particularly in heart tissue, [6] [7] which produces prolonged intracardiac conduction time and can lead to heart failure following even relatively minor overdoses. [8] [9] [10] [11] The toxicity of this metabolite makes dextropropoxyphene up to 10 times more likely to cause death following overdose compared to other similar mild opioid analgesics, [12] and has led to dextropropoxyphene being withdrawn from the market in some countries. [13]

Because norpropoxyphene has a long half-life in the body of up to 36 hours (compared to around 6–12 hours for dextropropoxyphene), it can accumulate in tissues during chronic use of dextropropoxyphene-containing medications, especially in people whose excretion of drugs is slower than normal such as young children, the elderly, and individuals with reduced kidney or liver function, and so side effects including serious adverse events are more common in these groups and use of dextropropoxyphene should be avoided where possible. [14] [15] [16]

Related Research Articles

<span class="mw-page-title-main">Paracetamol</span> Common medication for pain and fever

Paracetamol is a non-opioid analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is a widely used over the counter medication and common brand names include Tylenol and Panadol.

<span class="mw-page-title-main">Ibuprofen</span> Medication used for treating pain, fever, and inflammation

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used orally or intravenously. It typically begins working within an hour.

<span class="mw-page-title-main">Dextropropoxyphene</span> Withdrawn opioid medication

Dextropropoxyphene is an analgesic in the opioid category, patented in 1955 and manufactured by Eli Lilly and Company. It is an optical isomer of levopropoxyphene. It is intended to treat mild pain and also has antitussive and local anaesthetic effects. The drug has been taken off the market in Europe and the US due to concerns of fatal overdoses and heart arrhythmias. It is still available in Australia, albeit with restrictions after an application by its manufacturer to review its proposed banning. Its onset of analgesia is said to be 20–30 minutes and peak effects are seen about 1.5–2.0 hours after oral administration.

<span class="mw-page-title-main">Zopiclone</span> Hypnotic medication

Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine used to treat difficulty sleeping. Zopiclone is molecularly distinct from benzodiazepine drugs and is classed as a cyclopyrrolone. However, zopiclone increases the normal transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via modulating GABAA receptors similarly to the way benzodiazepine drugs do.

<span class="mw-page-title-main">Nitrazepam</span> Benzodiazepine sedative

Nitrazepam, sold under the brand name Mogadon among others, is a hypnotic drug of the benzodiazepine class used for short-term relief from severe, disabling anxiety and insomnia. It also has sedative (calming) properties, as well as amnestic, anticonvulsant, and skeletal muscle relaxant effects.

<span class="mw-page-title-main">Primidone</span> Barbiturate medication used to treat seizures and tremors

Primidone, sold under various brand names, is a barbiturate medication that is used to treat partial and generalized seizures and essential tremors. It is taken by mouth.

<span class="mw-page-title-main">Quazepam</span> Benzodiazipine

Quazepam, sold under brand name Doral among others, is a relatively long-acting benzodiazepine derivative drug developed by the Schering Corporation in the 1970s. Quazepam is used for the treatment of insomnia including sleep induction and sleep maintenance. Quazepam induces impairment of motor function and has relatively selective hypnotic and anticonvulsant properties with considerably less overdose potential than other benzodiazepines. Quazepam is an effective hypnotic which induces and maintains sleep without disruption of the sleep architecture.

<span class="mw-page-title-main">Morphine-6-glucuronide</span> Chemical compound

Morphine-6-glucuronide (M6G) is a major active metabolite of morphine. M6G is formed from morphine by the enzyme UGT2B7. It has analgesic effects more potent than morphine. M6G can accumulate to toxic levels in kidney failure.

<span class="mw-page-title-main">Moclobemide</span> Antidepressant

Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the UK and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.

<span class="mw-page-title-main">Nordazepam</span> Benzodiazepine derivative medication

Nordazepam is a 1,4-benzodiazepine derivative. Like other benzodiazepine derivatives, it has amnesic, anticonvulsant, anxiolytic, muscle relaxant, and sedative properties. However, it is used primarily in the treatment of anxiety disorders. It is an active metabolite of diazepam, chlordiazepoxide, clorazepate, prazepam, pinazepam, and medazepam.

<span class="mw-page-title-main">Brotizolam</span> Benzodiazepine

Brotizolam is a sedative-hypnotic thienotriazolodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to other short-acting hypnotic benzodiazepines such as triazolam or midazolam. It is used in the short-term treatment of severe insomnia. Brotizolam is a highly potent and short-acting hypnotic, with a typical dose ranging from 0.125 to 0.25 milligrams, which is rapidly eliminated with an average half-life of 4.4 hours.

<span class="mw-page-title-main">Grapefruit–drug interactions</span> Drug interactions with grapefruit juice

Some fruit juices and fruits can interact with numerous drugs, in many cases causing adverse effects. The effect is most studied with grapefruit and grapefruit juice, but similar effects have been observed with certain other citrus fruits.

<span class="mw-page-title-main">Gliclazide</span> Chemical compound

Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. It is used when dietary changes, exercise, and weight loss are not enough. It is taken by mouth.

<span class="mw-page-title-main">Codeine</span> Opiate and prodrug of morphine used to treat pain

Codeine is an opiate and prodrug of morphine mainly used to treat pain, coughing, and diarrhea. It is also commonly used as a recreational drug. It is found naturally in the sap of the opium poppy, Papaver somniferum. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or a nonsteroidal anti-inflammatory drug (NSAID) such as aspirin or ibuprofen. Evidence does not support its use for acute cough suppression in children or adults. In Europe, it is not recommended as a cough medicine in those under 12 years of age. It is generally taken by mouth. It typically starts working after half an hour, with maximum effect at two hours. Its effects last for about four to six hours. Codeine exhibits abuse potential similar to other opioid medications.

<span class="mw-page-title-main">Desmetramadol</span> Opioid painkiller medication

Desmetramadol (INN), also known as O-desmethyltramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. Tramadol is demethylated by the liver enzyme CYP2D6 to desmetramadol in the same way as codeine, and so similarly to the variation in effects seen with codeine, individuals who have a less active form of CYP2D6 will tend to have reduced analgesic effects from tramadol. Because desmetramadol itself does not need to be metabolized to induce an analgesic effect, it can be used in individuals with low CYP2D6 activity unlike tramadol.

Paracetamol/metoclopramide hydrochloride is an oral fixed dose combination prescription medication containing the analgesic paracetamol (500 mg) and the anti-emetic metoclopramide hydrochloride (5 mg). Formulated as a tablet and as sachets of a water-soluble powder, it is sold under the trade name Paramax by Sanofi-Synthelabo, and in Switzerland as Migraeflux MCP, in Australia it is sold as Meteclomax and Anagraine.

<span class="mw-page-title-main">Paracetamol poisoning</span> Toxicity due to paracetamol overdose

Paracetamol poisoning, also known as acetaminophen poisoning, is caused by excessive use of the medication paracetamol (acetaminophen). Most people have few or non-specific symptoms in the first 24 hours following overdose. These symptoms include feeling tired, abdominal pain, or nausea. This is typically followed by absence of symptoms for a couple of days, after which yellowish skin, blood clotting problems, and confusion occurs as a result of liver failure. Additional complications may include kidney failure, pancreatitis, low blood sugar, and lactic acidosis. If death does not occur, people tend to recover fully over a couple of weeks. Without treatment, death from toxicity occurs 4 to 18 days later.

<span class="mw-page-title-main">Benzodiazepine overdose</span> Medical condition

Benzodiazepine overdose describes the ingestion of one of the drugs in the benzodiazepine class in quantities greater than are recommended or generally practiced. The most common symptoms of overdose include central nervous system (CNS) depression, impaired balance, ataxia, and slurred speech. Severe symptoms include coma and respiratory depression. Supportive care is the mainstay of treatment of benzodiazepine overdose. There is an antidote, flumazenil, but its use is controversial.

<span class="mw-page-title-main">Tiamenidine</span> Chemical compound

Tiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is an imidazoline compound that shares many of the pharmacological properties of clonidine. It is a centrally-acting α2 adrenergic receptor agonist (IC50 = 9.1 nM). It also acts as an α1-adrenergic receptor agonist to a far lesser extent (IC50 = 4.85 μM). In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output. It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis under the brand name Sundralen for the management of essential hypertension.

A chiral switch is a chiral drug that has already approved as racemate but has been re-developed as a single enantiomer. The term chiral switching was introduced by Agranat and Caner in 1999 to describe the development of single enantiomers from racemate drugs. For example, levofloxacin is a chiral switch of racemic ofloxacin. The essential principle of a chiral switch is that there is a change in the status of chirality. In general, the term chiral switch is preferred over racemic switch because the switch is usually happening from a racemic drug to the corresponding single enantiomer(s). It is important to understand that chiral switches are treated as a selection invention. A selection invention is an invention that selects a group of new members from a previously known class on the basis of superior properties. To express the pharmacological activities of each of the chiral twins of a racemic drug two technical terms have been coined eutomer and distomer. The member of the chiral twin that has greater physiological activity is referred to as the eutomer and the other one with lesser activity is referred to as distomer. The eutomer/distomer ratio is called the eudisimic ratio and reflects the degree of enantioselectivity of the biological activity.

References

  1. Somogyi AA, Menelaou A, Fullston SV (October 2004). "CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement". Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 34 (10): 875–87. doi:10.1080/00498250400008371. PMID   15764408. S2CID   7680532.
  2. Gustafson A, Gustafsson B (1976). "Acute poisoning with dextropropoxyphene. Clinical symptoms and plasma concentrations". Acta Medica Scandinavica. 200 (4): 241–8. doi:10.1111/j.0954-6820.1976.tb08226.x. PMID   983792.
  3. McBay AJ (August 1976). "Propoxyphene and norpropoxyphene concentrations in blood and tissues in cases of fatal overdose". Clinical Chemistry. 22 (8): 1319–21. doi: 10.1093/clinchem/22.8.1319 . PMID   949842.
  4. Nickander RC, Emmerson JL, Hynes MD, Steinberg MI, Sullivan HR (August 1984). "Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review". Human Toxicology. 3 Suppl: 13S–36S. doi:10.1177/096032718400300103. PMID   6090306. S2CID   1333582.
  5. Nickander R, Smits SE, Steinberg MI (January 1977). "Propoxyphene and norpropoxyphene: pharmacologic and toxic effects in animals". The Journal of Pharmacology and Experimental Therapeutics. 200 (1): 245–53. PMID   13200.
  6. Lund-Jacobsen H (March 1978). "Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits". Acta Pharmacologica et Toxicologica. 42 (3): 171–8. doi:10.1111/j.1600-0773.1978.tb02187.x. PMID   580345.
  7. Ulens C, Daenens P, Tytgat J (December 1999). "Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents". Cardiovascular Research. 44 (3): 568–78. doi: 10.1016/s0008-6363(99)00258-8 . PMID   10690289.
  8. Young RJ (July 1983). "Dextropropoxyphene overdosage. Pharmacological considerations and clinical management". Drugs. 26 (1): 70–9. doi:10.2165/00003495-198326010-00004. PMID   6349964. S2CID   46978533.
  9. Lawson AA, Northridge DB (1987). "Dextropropoxyphene overdose. Epidemiology, clinical presentation and management". Medical Toxicology and Adverse Drug Experience. 2 (6): 430–44. doi:10.1007/BF03259877. PMID   3323775. S2CID   13452948.
  10. Afshari R, Maxwell S, Dawson A, Bateman DN (2005). "ECG abnormalities in co-proxamol (paracetamol/dextropropoxyphene) poisoning". Clinical Toxicology. 43 (4): 255–9. doi:10.1081/CLT-66069. PMID   16035201. S2CID   36817890.
  11. Simkin S, Hawton K, Sutton L, Gunnell D, Bennewith O, Kapur N (March 2005). "Co-proxamol and suicide: preventing the continuing toll of overdose deaths". QJM. 98 (3): 159–70. doi: 10.1093/qjmed/hci026 . PMID   15728397.
  12. Afshari R, Good AM, Maxwell SR, Bateman DN (October 2005). "Co-proxamol overdose is associated with a 10-fold excess mortality compared with other paracetamol combination analgesics". British Journal of Clinical Pharmacology. 60 (4): 444–7. doi:10.1111/j.1365-2125.2005.02468.x. PMC   1884826 . PMID   16187978.
  13. Sandilands EA, Bateman DN (August 2008). "Co-proxamol withdrawal has reduced suicide from drugs in Scotland". British Journal of Clinical Pharmacology. 66 (2): 290–3. doi:10.1111/j.1365-2125.2008.03206.x. PMC   2492929 . PMID   18489609.
  14. Gibson TP, Giacomini KM, Briggs WA, Whitman W, Levy G (May 1980). "Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient". Clinical Pharmacology and Therapeutics. 27 (5): 665–70. doi:10.1038/clpt.1980.94. PMID   7371364. S2CID   24099122.
  15. Inturrisi CE, Colburn WA, Verebey K, Dayton HE, Woody GE, O'Brien CP (February 1982). "Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene". Clinical Pharmacology and Therapeutics. 31 (2): 157–67. doi:10.1038/clpt.1982.25. PMID   7056023. S2CID   38421623.
  16. Flanagan RJ, Johnston A, White AS, Crome P (October 1989). "Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage". British Journal of Clinical Pharmacology. 28 (4): 463–9. doi:10.1111/j.1365-2125.1989.tb03527.x. PMC   1379997 . PMID   2590604.